NDAORAL-21TABLET
Approved
Oct 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORTHO-NOVUM 1/35-21 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1974.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/35-21 is an oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin) in a 21-day tablet formulation. It prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial tissue. This is a foundational hormonal contraceptive that has been standard-of-care for five decades.
LOE Approaching
Product is at end-of-life with moderate competitive pressure (30/100); expect contracting teams and focus on cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
ORTHO-NOVUM 1/35-21 represents a legacy, mature product with zero linked job opportunities currently—indicating minimal hiring or team expansion. Working on this product offers stability but limited growth trajectory; career progression depends on contributing to cost optimization, generic defense, or transition to next-generation formulations within the contraceptive portfolio.
Brand Manager
Worked on ORTHO-NOVUM 1/35-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.